{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:56:54Z","timestamp":1784185014151,"version":"3.55.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.gore.2025.101697","type":"journal-article","created":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T00:02:22Z","timestamp":1739664142000},"page":"101697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Case report of stage IIIC low-grade serous ovarian cancer in a 13-year-old female treated with novel therapy"],"prefix":"10.1016","volume":"58","author":[{"given":"Ishara","family":"Handagala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"NewBill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16_suppl","key":"10.1016\/j.gore.2025.101697_b0015","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1200\/JCO.2022.40.16_suppl.5522","article-title":"A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma","volume":"40","author":"Cobb","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2025.101697_b0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol."},{"issue":"10324","key":"10.1016\/j.gore.2025.101697_b0030","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.gore.2025.101697_b0035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2025.101697_b0040","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/AOG.0000000000001867","article-title":"Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer","volume":"129","author":"Gockley","year":"2017","journal-title":"Obstet. Gynecol."},{"issue":"32","key":"10.1016\/j.gore.2025.101697_b0055","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: Binimetinib Versus Physician\u2019s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"Journal of Clinical Oncology; Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.gore.2025.101697_b0060","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1006\/gyno.2000.6020","article-title":"Low-Grade Ovarian Cancer in an Adolescent Patient","volume":"80","author":"Parker","year":"2001","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.gore.2025.101697_b0065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian Low-grade and High-grade Serous Carcinoma","volume":"16","author":"Vang","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.gore.2025.101697_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102497","article-title":"Low grade serous ovarian cancer \u2013 A rare disease with increasing therapeutic options","volume":"112","author":"Zwimpfer","year":"2023","journal-title":"Cancer Treat. Rev."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925000220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925000220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T23:03:24Z","timestamp":1744844604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578925000220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":9,"alternative-id":["S2352578925000220"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2025.101697","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Case report of stage IIIC low-grade serous ovarian cancer in a 13-year-old female treated with novel therapy","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2025.101697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101697"}}